Pfizer hikes 2021 outlook after vaccine boosts sales, profit
The Hindu
The COVID-19 vaccine became Pfizer’s top seller, bringing in nearlt half its revenue
Strong sales of its COVID-19 vaccine and other medicines helped Pfizer nearly double its second-quarter revenue and boost its profit an impressive 59%, beating Wall Street expectations and leading the drug giant to sharply hike its 2021 sales and profit forecasts. Amid the surging coronavirus pandemic, the COVID-19 vaccine became Pfizer's top seller, bringing in nearly half its revenue — $7.84 billion from direct sales and revenue split with its partner, Germany's BioNTech. Pfizer now anticipates revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it's contracted to provide by year end. That doesn't include a contract struck last week to provide an additional 200 million doses to the U.S.More Related News
EU and Israel in war of words as ties nosedive ahead of Spain, Ireland recognizing Palestinian state
EU-Israel relations strained over Palestinian state recognition, with threats of sanctions and ICC involvement in conflict.